These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 16232203

  • 1. Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements.
    Wang WD, Li R, Chen ZT, Li DZ, Duan YZ, Cao ZH.
    Cancer Sci; 2005 Oct; 96(10):706-12. PubMed ID: 16232203
    [Abstract] [Full Text] [Related]

  • 2. Transcriptional control of viral gene therapy by cisplatin.
    Park JO, Lopez CA, Gupta VK, Brown CK, Mauceri HJ, Darga TE, Manan A, Hellman S, Posner MC, Kufe DW, Weichselbaum RR.
    J Clin Invest; 2002 Aug; 110(3):403-10. PubMed ID: 12163460
    [Abstract] [Full Text] [Related]

  • 3. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1.
    Ou W, Ye S, Yang W, Wang Y, Ma Q, Yu C, Shi H, Yuan Z, Zhong G, Ren J, Zhu W, Wei Y.
    Cancer Gene Ther; 2012 Jul; 19(7):489-98. PubMed ID: 22576699
    [Abstract] [Full Text] [Related]

  • 4. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene.
    Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA.
    Cancer Res; 1994 May 01; 54(9):2287-91. PubMed ID: 8162565
    [Abstract] [Full Text] [Related]

  • 5. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent.
    Ogawa N, Fujiwara T, Kagawa S, Nishizaki M, Morimoto Y, Tanida T, Hizuta A, Yasuda T, Roth JA, Tanaka N.
    Int J Cancer; 1997 Nov 04; 73(3):367-70. PubMed ID: 9359484
    [Abstract] [Full Text] [Related]

  • 6. Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector.
    Rohr UP, Wulf MA, Stahn S, Heyd F, Steidl U, Fenk R, Opalka B, Pitschke G, Prisack HB, Bojar H, Haas R, Kronenwett R.
    Cancer Gene Ther; 2003 Dec 04; 10(12):898-906. PubMed ID: 14712316
    [Abstract] [Full Text] [Related]

  • 7. Aloperine in combination with therapeutic adenoviral vector synergistically suppressed the growth of non-small cell lung cancer.
    Muhammad T, Sakhawat A, Khan AA, Huang H, Khan HR, Huang Y, Wang J.
    J Cancer Res Clin Oncol; 2020 Apr 04; 146(4):861-874. PubMed ID: 32088783
    [Abstract] [Full Text] [Related]

  • 8. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.
    Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, Ji L.
    Cancer Res; 2004 Aug 15; 64(16):5745-52. PubMed ID: 15313915
    [Abstract] [Full Text] [Related]

  • 9. Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo.
    Ren X, Liu H, Zhang M, Wang M, Ma S.
    Mol Med Rep; 2016 Sep 15; 14(3):2431-8. PubMed ID: 27484725
    [Abstract] [Full Text] [Related]

  • 10. Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer.
    Li D, Zhang Y, Xie Y, Xiang J, Zhu Y, Yang J.
    Cancer Gene Ther; 2013 Apr 15; 20(4):251-9. PubMed ID: 23470565
    [Abstract] [Full Text] [Related]

  • 11. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A, Cao W, Liu X, Zhang Y, Ma Y, Xu R, Zhang R, Liu X, Zhou S, Wang R, Liu J, Tang X.
    J Cancer Res Clin Oncol; 2020 Jul 15; 146(7):1737-1749. PubMed ID: 32342201
    [Abstract] [Full Text] [Related]

  • 12. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
    Coxon A, Ziegler B, Kaufman S, Xu M, Wang H, Weishuhn D, Schmidt J, Sweet H, Starnes C, Saffran D, Polverino A.
    Mol Cancer; 2012 Sep 19; 11():70. PubMed ID: 22992329
    [Abstract] [Full Text] [Related]

  • 13. Enhanced induction of Bax gene expression in H460 and H1299 cells with the combined treatment of cisplatin and adenovirus mediated wt-p53 gene transfer.
    Choi JH, Ahn KS, Kim J, Hong YS.
    Exp Mol Med; 2000 Mar 31; 32(1):23-8. PubMed ID: 10762058
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model.
    Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA.
    J Natl Cancer Inst; 1994 Oct 05; 86(19):1458-62. PubMed ID: 8089864
    [Abstract] [Full Text] [Related]

  • 15. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S, Yang W, Wang Y, Ou W, Ma Q, Yu C, Ren J, Zhong G, Shi H, Yuan Z, Su X, Zhu W.
    Int J Mol Med; 2013 Jan 05; 31(1):33-42. PubMed ID: 23128378
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
    Deng WG, Wu G, Ueda K, Xu K, Roth JA, Ji L.
    Cancer Gene Ther; 2008 Jan 05; 15(1):29-39. PubMed ID: 17828283
    [Abstract] [Full Text] [Related]

  • 17. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
    Maemondo M, Saijo Y, Narumi K, Kikuchi T, Usui K, Tazawa R, Matsumoto K, Nakamura T, Sasaki K, Takahashi M, Niitsu Y, Nukiwa T.
    Cancer Res; 2004 Jul 01; 64(13):4611-20. PubMed ID: 15231673
    [Abstract] [Full Text] [Related]

  • 18. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes.
    Zou Y, Zong G, Ling YH, Hao MM, Lozano G, Hong WK, Perez-Soler R.
    J Natl Cancer Inst; 1998 Aug 05; 90(15):1130-7. PubMed ID: 9701362
    [Abstract] [Full Text] [Related]

  • 19. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts.
    Kawabe S, Munshi A, Zumstein LA, Wilson DR, Roth JA, Meyn RE.
    Int J Radiat Biol; 2001 Feb 05; 77(2):185-94. PubMed ID: 11236925
    [Abstract] [Full Text] [Related]

  • 20. Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy.
    Bickenbach KA, Veerapong J, Shao MY, Mauceri HJ, Posner MC, Kron SJ, Weichselbaum RR.
    Cancer Gene Ther; 2008 Mar 05; 15(3):133-9. PubMed ID: 18157146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.